• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Pfizer again?

Quote
















anonymous said:
Nope!

PFE is not interested in AGN. That ship has sailed people.
Click to expand...

Why not? They can get the Botox franchise, which is what they’ve wanted all along, at a fraction of the cost they were going to pay 2 years ago. They can sell off or discontinue everything else, making the deal more attractive. Sanders won’t get his nearly 1/2 Billion dollar pay day like he would have but at this point it’s better than nothing
 




anonymous said:
Why not? They can get the Botox franchise, which is what they’ve wanted all along, at a fraction of the cost they were going to pay 2 years ago. They can sell off or discontinue everything else, making the deal more attractive. Sanders won’t get his nearly 1/2 Billion dollar pay day like he would have but at this point it’s better than nothing
Click to expand...

They wanted the tax domicile, period. the first year tax savings alone were worth 10x any product revenues. Now that the corporate tax reform is in place the tax savings in the original deal just aren’t there.
 




anonymous said:
They wanted the tax domicile, period. the first year tax savings alone were worth 10x any product revenues. Now that the corporate tax reform is in place the tax savings in the original deal just aren’t there.
Click to expand...





Not only that, but PFE is not going to take a gamble on a pipeline that has only 2 potential drugs which have a 50-75% chance of approval even with good safety studies. Botox is worth lots but they are not interested in just that.
 




Top Bottom
Back
Quote